Results 191 to 200 of about 785,489 (353)
Supplementary Table S1 from Emergence of Multiple <i>EGFR</i> Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
, 2023 Sabrina Arena, Beatríz Bellosillo, Giulia Siravegna, Alejandro Martínez, Israel Cañadas, Luca Lazzari, Noelia Ferruz, Mariangela Russo, Sandra Misale, Iria González, Mar Iglesias, Elena Gavilán, Giorgio Corti, Sebastijan Hobor, Giovanni Crisafulli, Marta Salido, Juan M. Sánchez, Alba Dalmases, Joaquim Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, Clara Montagut +24 moreopenalex +1 more sourceSanggenol L Enhances Temozolomide Drug Sensitivity by Inhibiting Mitophagy and Inducing Apoptosis Through the Regulation of the TRIM16‐OPTN Axis in Glioblastoma
Advanced Science, EarlyView.Sanggenol L, a flavonoid from mulberry, enhances glioblastoma sensitivity to temozolomide by inhibiting mitophagy and inducing apoptosis through TRIM16‐mediated OPTN degradation. In animal studies, liposomal delivery of Sanggenol L significantly improves the efficacy of its combination with TMZ, providing new insights into glioblastoma treatment ...Hongbo Chang, Jianbing Hou, Xin Hu, Nana Hou, Minghao Xu, Yi Du, Jingyang Xu, Yongzhao Wang, Zhuohao Xie, Junbo Shi, Yundong Zhang, Hongjuan Cui +11 morewiley +1 more sourceSupplemental Figure 2 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers
, 2023 Michael Offin, Hira Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus Schultz, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann +14 moreopenalex +1 more sourceDiscovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity
Advanced Science, EarlyView.KG‐FP‐003, a highly potent TEAD‐YAP PROTAC derived from the patented inhibitor is developed. It selectively degrades endogenous TEAD proteins in HiBiT systems without IMiD‐related off‐target effects. Screening across 867 cancer cell lines revealed broad and superior anti‐tumor activity, highlighting its therapeutic potential through targeted TEAD ...Linhui Cao, Jing Yang, Yuhang Liu, Xiaotong Chen, Yufang Shi, Yunshuo Zhao, Yong Zhang, Jian Chen, Bowen Li, Wuqiang Wen, Lu Chen, Bo Peng, Lu Huang, Yanli Sun, Lixin Zhou, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Zhixiang Guo, Jing Xing, Guangya Zhu, Yazhou Wang, Baishan Jiang, Jing Lu, Kehao Zhao, Wenchao Lu +25 morewiley +1 more sourceEPI-14-1149 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
, 2023 Wolfgang Schuette, Peter Schirmacher, Wilfried Eberhardt, Juergen R. Fischer, J.-Matthias Graf von der Schulenburg, J. Mezger, Christian Schumann, Monika Serke, Silke Zaun, Manfred Dietel, Michael Thomas +10 moreopenalex +1 more sourceFeatures of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer [PDF]
, 2023 Shidan Wang, Ruichen Rong, Donghan M. Yang, Junya Fujimoto, Justin A. Bishop, Shirley Yan, Ling Cai, Carmen Behrens, Lynne D. Berry, Clare Wilhelm, Dara L. Aisner, Lynette M. Sholl, Bruce E. Johnson, David J. Kwiatkowski, Ignacio I. Wistuba, Paul A. Bunn, John D. Minna, Guanghua Xiao, Mark G. Kris, Yang Xie +19 moreopenalex +1 more sourcePhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Journal of Clinical Oncology, 2013 L. Sequist, J. Yang, N. Yamamoto, K. O'Byrne, V. Hirsh, T. Mok, Sarayut Lucien Geater, S. Orlov, C. Tsai, M. Boyer, W. Su, J. Bennouna, T. Kato, V. Gorbunova, K. Lee, R. Shah, D. Massey, V. Zazulina, M. Shahidi, M. Schuler +19 moresemanticscholar +1 more sourceA Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery
Advanced Science, EarlyView.This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...Huarong Zhang, Chaohu Wang, Jun Fan, Zexin Chen, Haoying Yu, Yawen Bai, Tingcheng Zhang, Qianchao Zhu, Yiwen Feng, Peirong Niu, Jiaqian Chen, Liping Yang, Xueying Li, Lei Yu, Songtao Qi, Yi Liu +15 morewiley +1 more sourceTackling Allergic Airway Inflammation with Organic Sheet‐Like Nanoplatforms by Targeted Elimination of Epithelial Small Extracellular Vesicles
Advanced Science, EarlyView.In this work, “inorganic‐free” nanosheets, named PNSE are developed using template‐based synthesis technology. The functionalized organic nanosheets exhibit low cytotoxicity, mild protein adsorption, and potent binding efficacy to epithelial sEVs.Zhaoxu Tu, Junyan Lin, Zhixin Li, Yuefei Zhu, Changyi Xu, Zihan Qiu, Qiumin Wang, Yang Ye, Yihui Wen, Jian Li, Kam W. Leong, Weiping Wen +11 morewiley +1 more source
